Literature DB >> 11281978

Number of episodes and antidepressant response in major depression.

Russell T. Joffe1, L. Trevor Young, Anthony J. Levitt, Glenda MacQueen, Michael J. Marriott, Janine Robb.   

Abstract

Current series of depression suggests that episodes of major depression sensitize a patient to further episodes so that the illness adopts a recurrent course. This suggested pathophysiological process may also lead to increased risk of treatment resistance and a chronic course of illness. This hypothesis has received little empirical support and, if correct, would suggest that greater number of episodes would lead to a decreased response to antidepressants. We examined this in a cohort of outpatients with major depressive disorder. We observed that initial severity of depression and duration of treatment, but not number of previous episodes, was related to treatment outcome. Our findings are discussed in relation to prevailing theories of the pathophysiology of depression and suggestions for further studies are made.

Entities:  

Year:  1999        PMID: 11281978     DOI: 10.1017/S1461145799001443

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  3 in total

Review 1.  Risk for recurrence in depression.

Authors:  Stephanie L Burcusa; William G Iacono
Journal:  Clin Psychol Rev       Date:  2007-03-03

2.  Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial.

Authors:  Edward S Friedman; Lori L Davis; Sidney Zisook; Stephen R Wisniewski; Madhukar H Trivedi; Maurizio Fava; A John Rush
Journal:  Eur Neuropsychopharmacol       Date:  2011-09-14       Impact factor: 4.600

3.  An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life.

Authors:  Atsushi Kuga; Toshinaga Tsuji; Shinji Hayashi; Shinji Fujikoshi; Hirofumi Tokuoka; Aki Yoshikawa; Rodrigo Escobar; Kazuhide Tanaka; Takaharu Azekawa
Journal:  Neuropsychiatr Dis Treat       Date:  2017-08-04       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.